罗米地辛作为早期HIV-1治愈研究组成部分的潜在作用。 - Suppr

Suppr

超能文献

The potential role for romidepsin as a component in early HIV-1 curative efforts.

作者信息

Gunst Jesper Damsgaard, Tolstrup Martin, Rasmussen Thomas Aagaard, Søgaard Ole Schmeltz

机构信息

a Department of Infectious Diseases , Aarhus University Hospital , Aarhus N , Denmark.

b Institute of Clinical Medicine , Aarhus University , Aarhus N , Denmark.

出版信息

Expert Rev Anti Infect Ther. 2016;14(5):447-50. doi: 10.1586/14787210.2016.1164031. Epub 2016 Mar 24.

DOI:10.1586/14787210.2016.1164031

PMID:26953620

Abstract

摘要

相似文献

The potential role for romidepsin as a component in early HIV-1 curative efforts.

Expert Rev Anti Infect Ther. 2016;14(5):447-50. doi: 10.1586/14787210.2016.1164031. Epub 2016 Mar 24.

HIVconsv Vaccines and Romidepsin in Early-Treated HIV-1-Infected Individuals: Safety, Immunogenicity and Effect on the Viral Reservoir (Study BCN02).

Front Immunol. 2020 May 6;11:823. doi: 10.3389/fimmu.2020.00823. eCollection 2020.

[Alarm clock for dormant HI viruses].

MMW Fortschr Med. 2014 Oct 9;156(17):32.

The search for a cure for persistent HIV reservoirs.

AIDS Rev. 2011 Apr-Jun;13(2):63-6.

Romidepsin: a novel histone deacetylase inhibitor for cancer.

Expert Opin Investig Drugs. 2011 Aug;20(8):1151-8. doi: 10.1517/13543784.2011.594437. Epub 2011 Jun 24.

Progress and challenges in the use of latent HIV-1 reactivating agents.

Acta Pharmacol Sin. 2015 Aug;36(8):908-16. doi: 10.1038/aps.2015.22. Epub 2015 Jun 1.

Phenothiazines in treatment of HIV infection (a review).

Acta Microbiol Immunol Hung. 2003;50(1):43-53. doi: 10.1556/AMicr.50.2003.1.5.

Romidepsin for the treatment of non-Hodgkin's lymphoma.

Expert Opin Investig Drugs. 2015;24(7):965-79. doi: 10.1517/13543784.2015.1041586. Epub 2015 May 4.

Multidrug-resistant HIV-1.

Clin Infect Dis. 2004 May 15;38(10):1507; author reply 1507. doi: 10.1086/383581.

New Insights into HIV-1 Persistence in Sanctuary Sites During Antiretroviral Therapy.

AIDS Rev. 2016 Jan-Mar;18(1):55.

引用本文的文献

Immunomodulation with IL-7 and IL-15 in HIV-1 infection.

J Virus Erad. 2023 Sep 5;9(3):100347. doi: 10.1016/j.jve.2023.100347. eCollection 2023 Sep.

Strategies for enhancing CAR T cell expansion and persistence in HIV infection.

Front Immunol. 2023 Aug 21;14:1253395. doi: 10.3389/fimmu.2023.1253395. eCollection 2023.

Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial.

Nat Med. 2022 Nov;28(11):2424-2435. doi: 10.1038/s41591-022-02023-7. Epub 2022 Oct 17.

Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial.

Lancet Microbe. 2022 Mar;3(3):e203-e214. doi: 10.1016/S2666-5247(21)00239-1. Epub 2022 Jan 24.

Fimepinostat, a novel dual inhibitor of HDAC and PI3K, effectively reverses HIV-1 latency without T cell activation.

J Virus Erad. 2019 Sep 18;5(3):133-137. doi: 10.1016/S2055-6640(20)30042-X.

Modeling Kick-Kill Strategies toward HIV Cure.

Front Immunol. 2017 Aug 28;8:995. doi: 10.3389/fimmu.2017.00995. eCollection 2017.

In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection.

Retrovirology. 2016 May 21;13(1):36. doi: 10.1186/s12977-016-0268-7.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

The potential role for romidepsin as a component in early HIV-1 curative efforts.

Expert Rev Anti Infect Ther. 2016;14(5):447-50. doi: 10.1586/14787210.2016.1164031. Epub 2016 Mar 24.

HIVconsv Vaccines and Romidepsin in Early-Treated HIV-1-Infected Individuals: Safety, Immunogenicity and Effect on the Viral Reservoir (Study BCN02).

Front Immunol. 2020 May 6;11:823. doi: 10.3389/fimmu.2020.00823. eCollection 2020.

[Alarm clock for dormant HI viruses].

MMW Fortschr Med. 2014 Oct 9;156(17):32.

The search for a cure for persistent HIV reservoirs.

AIDS Rev. 2011 Apr-Jun;13(2):63-6.

Romidepsin: a novel histone deacetylase inhibitor for cancer.

Expert Opin Investig Drugs. 2011 Aug;20(8):1151-8. doi: 10.1517/13543784.2011.594437. Epub 2011 Jun 24.

Progress and challenges in the use of latent HIV-1 reactivating agents.

Acta Pharmacol Sin. 2015 Aug;36(8):908-16. doi: 10.1038/aps.2015.22. Epub 2015 Jun 1.

Phenothiazines in treatment of HIV infection (a review).

Acta Microbiol Immunol Hung. 2003;50(1):43-53. doi: 10.1556/AMicr.50.2003.1.5.

Romidepsin for the treatment of non-Hodgkin's lymphoma.

Expert Opin Investig Drugs. 2015;24(7):965-79. doi: 10.1517/13543784.2015.1041586. Epub 2015 May 4.

Multidrug-resistant HIV-1.

Clin Infect Dis. 2004 May 15;38(10):1507; author reply 1507. doi: 10.1086/383581.

New Insights into HIV-1 Persistence in Sanctuary Sites During Antiretroviral Therapy.

AIDS Rev. 2016 Jan-Mar;18(1):55.

引用本文的文献

Immunomodulation with IL-7 and IL-15 in HIV-1 infection.

J Virus Erad. 2023 Sep 5;9(3):100347. doi: 10.1016/j.jve.2023.100347. eCollection 2023 Sep.

Strategies for enhancing CAR T cell expansion and persistence in HIV infection.

Front Immunol. 2023 Aug 21;14:1253395. doi: 10.3389/fimmu.2023.1253395. eCollection 2023.

Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial.

Nat Med. 2022 Nov;28(11):2424-2435. doi: 10.1038/s41591-022-02023-7. Epub 2022 Oct 17.

Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial.

Lancet Microbe. 2022 Mar;3(3):e203-e214. doi: 10.1016/S2666-5247(21)00239-1. Epub 2022 Jan 24.

Fimepinostat, a novel dual inhibitor of HDAC and PI3K, effectively reverses HIV-1 latency without T cell activation.

J Virus Erad. 2019 Sep 18;5(3):133-137. doi: 10.1016/S2055-6640(20)30042-X.

Modeling Kick-Kill Strategies toward HIV Cure.

Front Immunol. 2017 Aug 28;8:995. doi: 10.3389/fimmu.2017.00995. eCollection 2017.

In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection.

Retrovirology. 2016 May 21;13(1):36. doi: 10.1186/s12977-016-0268-7.